Summary
The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also investigate the difference responses in African American (AA) patients versus non-African American patients.
Objectives
The primary questions this study aims to answer are:
- To evaluate the very good partial response rate (VGPR) after 4 cycles of Dara-CyBord.
- To evaluate the renal response rate (RRR) after 4 cycles of Dara-CyBord.